A team led by NCI researchers has identified a potential biomarker that could help predict whether a tumor will respond to a relatively new class of targeted cancer drugs known as PARP inhibitors.
The team's findings, published September 27 in Oncotarget, showed that cancer cell lines with high expression levels of the gene SLFN11 were more sensitive than cells with low SLFN11 expression to the PARP inhibitors olaparib (Lynparza™) and talazoparib. Cancer cell lines in which the SLFN11 gene was inactivated were resistant to both drugs.
from Cancer via ola Kala on Inoreader http://ift.tt/2e7lfLc
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου